Drugs that contain Metformin Hydrochloride
1. Fortamet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8475841 | ANDRX LABS LLC | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6099859 | ANDRX LABS LLC | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US6495162 | ANDRX LABS LLC | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US7919116 | ANDRX LABS LLC | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6790459 | ANDRX LABS LLC | Methods for treating diabetes via administration of controlled release metformin |
Mar, 2021
(3 years ago) | |
| US6866866 | ANDRX LABS LLC | Controlled release metformin compositions |
Mar, 2021
(3 years ago) | |
Market Authorisation Date: 27 April, 2004
Treatment: Method of lowering blood glucose by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
FORTAMET family patents
2. Glucophage Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6475521 | EMD SERONO INC | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar, 2018
(6 years ago) | |
| US6660300 | EMD SERONO INC | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar, 2018
(6 years ago) | |
Market Authorisation Date: 13 October, 2000
Treatment: Method of treating patient with type 2 diabetes by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
GLUCOPHAGE XR family patents
3. Glumetza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6340475 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6635280 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6488962 | SANTARUS INC | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
| US6723340 | SANTARUS INC | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
| US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(10 months from now) | |
Market Authorisation Date: 03 June, 2005
Treatment: Indication of type ii diabetes
Dosage: TABLET, EXTENDED RELEASE;ORAL
GLUMETZA family patents
4. Riomet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6890957 | RANBAXY | Liquid formulation of metformin |
Sep, 2023
(7 months ago) | |
Market Authorisation Date: 11 September, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
RIOMET family patents
5. Riomet Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962336 | SUN PHARM | Extended release suspension compositions |
May, 2035
(11 years from now) | |
Market Authorisation Date: 29 August, 2019
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
RIOMET ER family patents